Microbot Medical Inc. is awaiting a marketing clearance decision from the FDA, and the Israel Innovation Authority has provided non-dilutive grant funding.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Microbot Medical Inc. is awaiting a marketing clearance decision from the FDA, and the Israel Innovation Authority has provided non-dilutive grant funding.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Israel Innovation Authority
support and investment arm of the Israeli government
Related events
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- The LIBERTY Endovascular Robotic System, developed by Microbot Medical Inc., is currently undergoing FDA review for clearance, with its patent expanding potential applications.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
Coverage
Newest first; wire copies grouped- GlobeNewswireMicrobot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Mar